Last updated: February 21, 2026
What is NDC 72572-0170?
NDC 72572-0170 refers to a specific drug package listed in the National Drug Code (NDC) database. According to available data, this NDC corresponds to Daratumumab (Darzalex) injection. It is used for treatment of multiple myeloma, marketed by Janssen Pharmaceuticals.
Market Landscape
Market Size and Demand
The multiple myeloma drug market experienced steady growth over recent years, driven by increased diagnosis rates and expanded treatment guidelines. The key factors influencing this market include:
- Prevalence: Multiple myeloma affects approximately 170,000 Americans, with annual incidence around 35,000 cases (SEER, 2020).
- Treatment landscape: Daratumumab is often used as part of combination therapy or as a monotherapy in relapsed/refractory cases.
- Market penetration: Darzalex holds a significant share, estimated at 40-50% of the first-line and relapsed settings in US markets.
Competitive Landscape
Daratumumab's primary competitors include:
- Elotuzumab (Empliciti): Monoclonal antibody targeting SLAMF7.
- Isatuximab (Sarclisa): Similar mechanism, from Sanofi.
- Carfilzomib (Kyprolis): Proteasome inhibitor.
Market Dynamics
- The approval of combination regimens with Darzalex has expanded use (e.g., Darzalex with lenalidomide and dexamethasone).
- The introduction of biosimilars is limited but expected to influence prices over the next 3-5 years.
- Increasing adoption in earlier lines of therapy is projected.
Pricing and Reimbursement Landscape
Current Price Points
Based on the most recent publicly available information, the wholesale acquisition cost (WAC) for a 10 mg/mL vial of Darzalex is approximately $4,000. The typical treatment course involves:
- An initial dose schedule of weekly infusions for cycles 1–3.
- Bi-weekly and monthly maintenance thereafter.
Price Components
- The drug cost per infusion typically ranges from $4,000 to $6,000 based on dosage and administration frequency.
- The annual treatment cost can exceed $150,000 per patient when factoring administration and supportive care.
Reimbursement Factors
- Medicare, Medicaid, and private insurers cover Darzalex with varying co-pay structures.
- Reimbursement policies favor outpatient infusion centers.
Price Projections
Short-Term (Next 1–2 Years)
- Prices are stable due to limited biosimilar competition.
- Manufacturers may adjust pricing periodically based on negotiation outcomes and market pressure.
- Payers are increasingly demanding value-based contracts, possibly influencing net prices.
Medium-Term (Next 3–5 Years)
- Biosimilars for Darzalex are entering the pipeline, possibly launching within the next 3 years.
- Price erosion is expected to range from 15% to 30% upon biosimilar entry.
- Market share could shift, reducing average selling prices by approximately 20% over this period.
Long-Term Outlook (Beyond 5 Years)
- Continued dose optimization and combination therapies may influence dosing and costs.
- Regulatory and patent exclusivity timelines could prolong or limit biosimilar competition, affecting pricing.
Key Assumptions
- Regulatory approval and market entry of biosimilars follow projected timelines.
- Payer negotiations maintain current reimbursement trends.
- No major policy shifts affect drug pricing or patent protections.
Summary Table: Price Projections
| Time Frame |
Estimated Price Change |
Notes |
| 0–2 years |
Stable or slight increase |
Market stability under current patents |
| 3–5 years |
15–30% price reduction |
Entry of biosimilars, market competition |
| Beyond 5 years |
Continued decline or stabilization |
Depending on biosimilar uptake and policy |
Key Takeaways
- NDC 72572-0170 (Daratumumab) maintains high list prices driven by limited biosimilar competition.
- Short-term prices are unlikely to decline significantly without biosimilar entry.
- Over 3–5 years, price erosion of 20% is probable due to biosimilar competition.
- Market adoption, combination therapy guidelines, and reimbursement policies heavily influence future price trajectories.
- Location-specific discounts and negotiations could substantially alter net prices.
FAQs
Q1: What is the main driver of Darzalex's current pricing?
A1:** Brand exclusivity and limited biosimilar competition maintain high list prices.
Q2: How might biosimilars impact the price of NDC 72572-0170?
A2:** Entry of biosimilars could lead to 15–30% price reductions within 3–5 years.
Q3: Are there any upcoming regulatory approvals that could change the market?
A3:** Biosimilars for Daratumumab are in late-stage development and could receive approval within the next 2–3 years.
Q4: How does the dosing schedule influence treatment costs?
A4:** Longer treatment durations and frequent infusions increase overall costs, with annual costs exceeding $150,000 per patient.
Q5: What are the reimbursement prospects for Darzalex?
A5:** Reimbursement remains favorable in outpatient settings, with insurance coverage supporting continued market demand.
References
- Cancer Statistics (2020). SEER Program. National Cancer Institute.
- Janssen Pharmaceuticals. Darzalex prescribing information.
- IQVIA. (2022). US Oncology Market Dynamics.
- U.S. Food and Drug Administration. (2020). Biosimilar Development Program.
